口服阿莫西林与阿莫西林/克拉维酸对犬粪便微生物多样性及β-内酰胺耐药的影响
本研究纳入42只犬(每组21只),分析口服阿莫西林或阿莫西林/克拉维酸前后粪便微生物及耐药变化。两组治疗期间均出现氨苄西林耐药大肠埃希菌比例增加,停药后耐药肠球菌增多;微生物丰富度与多样性下降后约1周恢复。阿莫西林/克拉维酸降低有益菌群丰度并富集埃希菌属,提示克拉维酸可能拓宽抗菌谱并损害肠道健康。
要点
- 口服阿莫西林或阿莫西林/克拉维酸均增加粪便中氨苄西林耐药大肠埃希菌比例。
- 治疗期间微生物丰富度和多样性下降,停药约1周后恢复至治疗前水平。
- 阿莫西林/克拉维酸降低Roseburia、Dialister等有益菌丰度并富集埃希菌属。
核心结论
- 克拉维酸与阿莫西林联用口服对耐药选择及微生物丰富度影响有限,但可能拓宽抗菌谱并对肠道健康产生负面影响。
研究设计与样本
- 研究纳入42只犬,每组21只,分别口服阿莫西林或阿莫西林/克拉维酸,于治疗前、治疗期间及停药后1周采集粪便,采用培养法和16S rRNA基因序列分析。
主要发现
- 两组治疗期间氨苄西林耐药大肠埃希菌比例均增加,治疗期间及停药后耐药肠球菌出现率和比例增加。
- 16S rRNA基因分析显示治疗期间微生物丰富度和多样性降低,停药约1周后恢复至治疗前状态。
- 阿莫西林与阿莫西林/克拉维酸对微生物丰富度和多样性的影响无显著差异。
- 阿莫西林/克拉维酸降低被认为有益菌群(如Roseburia、Dialister和Lachnospiraceae)的丰度并富集埃希菌属,但后者未获表型计数证实。
临床怎么用
- 临床使用阿莫西林/克拉维酸时需关注其对肠道有益菌群的潜在负面影响及耐药选择风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aminopenicillins with or without a β-lactamase inhibitor are widely used in both human and veterinary medicine. However, little is known about their differential impact on the gut microbiota and development of antimicrobial resistance. OBJECTIVES: To investigate changes in the faecal microbiota of dogs treated with amoxicillin or amoxicillin/clavulanic acid. METHODS: Faeces collected from 42 dogs (21 per treatment group) immediately before, during and 1 week after termination of oral treatment with amoxicillin or amoxicillin/clavulanic acid were analysed by culture and 16S rRNA gene sequence analysis. RESULTS: In both groups, bacterial counts on ampicillin selective agar revealed an increase in the proportion of ampicillin-resistant Escherichia coli during treatment, and an increased occurrence and proportion of ampicillin-resistant enterococci during and after treatment. 16S rRNA gene analysis showed reductions in microbial richness and diversity during treatment followed by a return to pre-treatment conditions approximately 1 week after cessation of amoxicillin or amoxicillin/clavulanic acid treatment. While no significant differences were observed between the effects of amoxicillin and amoxicillin/clavulanic acid on microbial richness and diversity, treatment with amoxicillin/clavulanic acid reduced the abundance of taxa that are considered part of the beneficial microbiota (such as Roseburia, Dialister and Lachnospiraceae) and enriched Escherichia, although the latter result was not corroborated by phenotypic counts. CONCLUSIONS: Our results suggest a limited effect of clavulanic acid on selection of antimicrobial resistance and microbial richness when administered orally in combination with amoxicillin. However, combination with this β-lactamase inhibitor appears to broaden the spectrum of amoxicillin, with potential negative consequences on gut health.
引用
- Espinosa-Gongora C, Jessen LR, Kieler IN, et al. Impact of oral amoxicillin and amoxicillin/clavulanic acid treatment on bacterial diversity and β-lactam resistance in the canine faecal microbiota. J Antimicrob Chemother. 2020. PMID: 31778166. doi:10.1093/jac/dkz458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。